CAJ | 학술논문

目的：观察红花黄色素注射液联合低分子肝素治疗不稳定型绞痛（UAP）的临床效果及安全性。方法选择2014年3月至2015年3月住院的UAP患者120例，完全随机分为观察组（60例）和对照组（60例），观察2组治疗前后UAP患者临床疗效、心绞痛发作频次与持续时间、心电图改善情况。结果2组治疗前后UAP患者临床疗效比较，总有效率治疗组高于对照组，2组比较差异有统计学意义[91.7%（56/60）比75.0%（45/60），P＜0.05]。治疗组心绞痛发作频次：治疗前（17.1±1.5）次/周，治疗后（3.6±0.6）次/周；发作持续时间：治疗前（16.5±3.2）min，治疗后（4.4±0.9）min。对照组心绞痛发作频次：治疗前（17.6±1.4）次/周，治疗后（7.8±1.3）次/周；发作持续时间：治疗前（15.2±3.1）min，治疗后（6.7±0.8）min。2组比较差异有统计学意义（P<0.05）。2组UAP患者心电图改善程度比较：治疗组总有效率51.6%（31/60），对照组总有效率35.0%（21/60）。2组比较差异有统计学意义（P<0.05）。结论红花黄色素天注射液联合低分子肝素治疗UAP安全有效。
목적：관찰홍화황색소주사액연합저분자간소치료불은정형교통（UAP）적림상효과급안전성。방법선택2014년3월지2015년3월주원적UAP환자120례，완전수궤분위관찰조（60례）화대조조（60례），관찰2조치료전후UAP환자림상료효、심교통발작빈차여지속시간、심전도개선정황。결과2조치료전후UAP환자림상료효비교，총유효솔치료조고우대조조，2조비교차이유통계학의의[91.7%（56/60）비75.0%（45/60），P＜0.05]。치료조심교통발작빈차：치료전（17.1±1.5）차/주，치료후（3.6±0.6）차/주；발작지속시간：치료전（16.5±3.2）min，치료후（4.4±0.9）min。대조조심교통발작빈차：치료전（17.6±1.4）차/주，치료후（7.8±1.3）차/주；발작지속시간：치료전（15.2±3.1）min，치료후（6.7±0.8）min。2조비교차이유통계학의의（P<0.05）。2조UAP환자심전도개선정도비교：치료조총유효솔51.6%（31/60），대조조총유효솔35.0%（21/60）。2조비교차이유통계학의의（P<0.05）。결론홍화황색소천주사액연합저분자간소치료UAP안전유효。
Objective To observe the saflfor yellow injection combined with low molecular weight heparin in treatment of unstable angina pectoris (UAP) the clinical efifcacy and safety. Methods The patients with unstable type in 2014 March to 2015 March in hospital 120 cases of angina pectoris were randomly divided into observation group (60 cases) and control group (60 cases), 2 groups were observed before and after treatment of UAP patients, the clinical curative effect of angina attack frequency and duration, the improvement in ECG. Results The 2 groups before and after treatment in patients with UAP clinical curative effect comparison, treatment group total effectiveness 91.7%(56/60), the comparison group total effectiveness 75%(45/60), 2 groups had signiifcant difference (P<0.05). Comparison of 2 groups of angina attack frequency and duration of angina pectoris, frequency (times/week):before treatment (17.1±1.5), after treatment(3.6±0.6);the duration of seizures (min):before treatment (17.6±1.4), after treatment (7.8±1.3). The control group angina attack frequency (times/week):before treatment (15.2±3.1), after treatment(6.7±0.8). There was signiifcant difference between 2 groups(P<0.05). 2 groups of unstable angina patients with ECG improvement:treatment group total effectiveness 51.6%(31/60), the comparison group total effectiveness 35%(21/60). There was signiifcant difference between 2 groups (P<0.05). Conclusion Saflfor yellow injection combined with low molecular weight heparin in treatment of UAP is safe and effective.